Are you nervous about next week? I am not! And I tell you why:
1) I have seen the preliminary safety data from the phase 1 on the type of adverse events observed in the vaccinated people. These are exactly the same type of adverse events which always can be seen in vaccines which work and they are clinical signs of the immune response which include also upregulating of some cytokines which cause the symptoms. They are basically the same line the day before you get the flu. Such effects have been also reported for Pfizer and Moderna. They are always seen when a vaccine works. Check out yourself if you are nervous - it will add to your confidence and calm.
2) I have said it several times here; this phase 1 is NOT a blinded study, but an OPEN label study (google: NCT04563702 ). And this means that the people at Vaxart MUST know at least since mid of December more or less the data, the first results on the immune response since November !
Would they hire so many high qualified (and well paid) staff related to production, if this phase 1 trial failed to show not only good safety data but also very promising data on the immune response ? Would the have moved to their new building ?
Phase 1 will be positive and this will trigger OWS money days of a very weeks after.
The world will need adapted vaccines and it won’t be enough to vaccinate the people in developed countries. The global population must be vaccinated - otherwise we will get again again new variants and we will be always some months behind the new variants spreading again around the globe.
The biggest weapon (or holy grail) we can use to fight this virus would be a DNA vector vaccine, because they can be adapted and produced faster than any other vaccine. Add that the Vaxart Tablett is the only vaccine which can be stored and transported at room temperatur. Alone these points make Vaxart to the best (so far only theoretical) solution. But on top we do not need a needle (another constrain less). That means also the time per vaccination will be much shorter. No queue (no infection risk), no waiting, no infection risk in African countries (reused needles), easy deliver by post or even my bike, Jeep, motorbike etc in Africa.....
If phase 1 is positiv - OWS simply cannot miss this opportunity, actually this duty to provide massive funding for Vaxart. Good that we know from the OWS Chief how he thinks about the „oral vaccine in phase 1).
Now that it seems that new variants threaten global economies even beyond this first round of vaccination and that we will need future updates/adapted vaccines, the potential role Vaxart could play in this global fight has significantly increased. IMO it is granted that soon after phase I OWS will massively fund Vaxart. Maybe we will get already first infos with phase 1 results that vaxart was invited to discuss with OWS...... |